MCID: BLD062
MIFTS: 64

Bile Duct Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Bile Duct Cancer

MalaCards integrated aliases for Bile Duct Cancer:

Name: Bile Duct Cancer 12 54 56 44 15
Bile Duct Carcinoma 12 15 17
Extrahepatic Bile Duct Carcinoma 12 15
Extrahepatic Bile Duct Cancer 12 54
Malignant Neoplasm of the Extrahepatic Bile Duct 12
Carcinoma of Extrahepatic Bile Duct 12
Bile Duct Extrahepatic Carcinoma 56
Ca Extrahepatic Bile Ducts 12
Bile Duct Neoplasms 45
Bile Duct Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4606 DOID:4682 DOID:4897
ICD9CM 36 156.1
MeSH 45 D001650
SNOMED-CT 69 70179006 93790004
ICD10 34 C24.0

Summaries for Bile Duct Cancer

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 70567Disease definitionCholangiocarcinoma (CCA) is a biliary tract cancer (BTC, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic.EpidemiologyThe prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies.Clinical descriptionCCA can occur in the intra or extra-hepatic biliary tract. A specific type of extra-hepatic CCA known as a Klatskin tumor (see this term) occurs at the junction where the left and right hepatic bile ducts meet the common bile duct (CBD). It is slightly more prevalent in males than females (1.3:1.0) and usually presents in the fifth to seventh decade of life. Clinical manifestations are not usually noted until an advanced disease stage. Extra-hepatic CCA manifests with signs of cholestasis (jaundice, pale stools, dark urine, pruritus), malaise, weight loss and/or progressive weakness. Intra-hepatic CCA may present with an abdominal mass or with non-specific symptoms of decreased appetite, weight loss, abdominal pain and malaise.EtiologyThe etiology is unknown and most cases of CCA occur sporadically. Risk factors include primary sclerosing cholangitis (see this term), secondary sclerosing cholangitis, chronic typhoid carriage, parasitic infections (Opisthochis viverrini and Clonorchis sinensis), exposure to thorotrast (x-ray contrast medium) and choledochal cysts, all of which cause chronic biliary inflammation.Diagnostic methodsDiagnosis is suspected on clinical and laboratory findings. Serum carbohydrate antigen (CA) 19-9 is the glycoprotein tumor marker most often used in the diagnosis of CCA. It is found to be elevated in 85% of patients. Increased CEA levels are also noted. Extra-hepatic tumors cause increased levels of alkaline phosphate (ALP), conjugated bilirubin and gamma-glutamyl transpeptidase (GGT) while intra-hepatic have only slightly elevated ALP levels. Abdominal imaging, visualization of the biliary tree and biopsies of the lesion are necessary for diagnosis. Magnetic resonance cholangiopancreatography (MRCP) provides information on intrahepatic metastases, biliary anatomy and tumor extension and is used in the staging of CCA. It has been advocated to replace endoscopic retrograde cholangiopancreatography (ERCP), a more invasive method. Visualization of the biliary tree and samples through brush cytology or bile duct biopsies are obtained with ERCP. A needle biopsy is performed in those with a liver mass. Extra-hepatic CCA is further divided into anatomical subtypes according to the Bismuth classification and a disease stage is given. Ultrasound, and contrast enhanced helical computerized computed tomography (CT) can be used in visualizing the extent of disease.Differential diagnosisIntra-hepatic CCA is often mistaken for metastatic adenocarcinoma. Carcinoma of the gallbladder (see this term), benign strictures and Mirizzi syndrome should be excluded.Management and treatmentSurgical resection is the only potentially curative treatment for CCA but recurrences after surgery are frequent. Unfortunately CCA is often diagnosed as unresectable because of local extension and/or metastases. Distal CCA arising from the CBD is often treated by pancreatoduodenectomy. More proximal CCA needs hepatic resection. Palliative management involves biliary drainage by inserting metal stents in the biliary tree to release the blockage. Adjuvant chemotherapy after surgery or palliative chemotherapy for unresectable CCA is indicated. Gemcitabine combined with cisplatin therapy is the standard treatment for unresectable biliary tract cancers, including CCA.PrognosisAs proximal CCA is usually not diagnosed until a late stage of disease, prognosis is poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors. Death is often due to biliary sepsis, cancer cachexia, malnutrition and liver failure.Visit the Orphanet disease page for more resources.

MalaCards based summary : Bile Duct Cancer, also known as bile duct carcinoma, is related to intrahepatic cholangiocarcinoma and in situ carcinoma. An important gene associated with Bile Duct Cancer is NCAM1 (Neural Cell Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pancrelipase and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A biliary tract cancer that is located in the bile duct.

MedlinePlus : 44 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. Symptoms can include Jaundice Itchy skin Fever Abdominal pain Tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. Treatments include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

Wikipedia : 77 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Bile Duct Cancer

Diseases in the Bile Duct Cancer family:

Bile Duct Carcinoma in Situ

Diseases related to Bile Duct Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
# Related Disease Score Top Affiliating Genes
1 intrahepatic cholangiocarcinoma 31.2 AFP EGFR KRAS KRT7 MUC1 MUC5AC
2 in situ carcinoma 30.4 CDKN2A EGFR TP53
3 mammary paget's disease 30.3 EGFR KRT7 MUC1
4 papillary carcinoma 30.3 KRT7 MET MUC1
5 adenosquamous carcinoma 30.3 EGFR KRAS KRT7 MUC1 TP53
6 small cell carcinoma 30.2 CDKN2A EGFR KRT7 NCAM1 TP53
7 adenoma 30.1 CCND1 KRAS SMAD4 TP53
8 cholangiocarcinoma 30.0 AFP ASPH CCND1 CDKN2A CEACAM5 EGFR
9 acinar cell carcinoma 30.0 AFP KRT7 SMAD4 TP53
10 bile duct adenocarcinoma 29.9 AFP CEACAM5 HRAS KRAS KRT7 MUC1
11 lynch syndrome 29.8 CCND1 CDKN2A EGFR KRAS TP53
12 bile duct cystadenocarcinoma 29.7 AFP CEACAM5 KRT7 MUC1 MUC5AC
13 mixed ductal-endocrine carcinoma 29.7 CEACAM5 MUC1 NCAM1 SMAD4
14 gallbladder cancer 29.7 CDKN2A CEACAM5 EGFR KRAS MUC1 TP53
15 renal cell carcinoma, nonpapillary 29.7 EGFR KRT7 MET MMP2 MUC1 VEGFA
16 mucinous adenocarcinoma 29.5 CDKN2A EGFR KRAS KRT7 MUC1
17 carcinosarcoma 29.5 HRAS KRAS KRT7 MUC1 TP53
18 adenocarcinoma 29.2 CCND1 CDKN2A EGFR HRAS KRAS MUC1
19 bladder cancer 29.0 CCND1 CDKN2A EGFR HRAS KRAS MMP2
20 gastric cancer 27.5 AFP CCND1 CDKN2A CEACAM5 EGFR KRAS
21 hepatocellular carcinoma 27.3 AFP CCND1 CDKN2A CEACAM5 EGFR HRAS
22 pancreas adenocarcinoma 27.0 CCND1 CDKN2A CEACAM5 EGFR HRAS KRAS
23 pancreatic cancer 27.0 CCND1 CDKN2A CEACAM5 EGFR HRAS KRAS
24 adenosquamous bile duct carcinoma 12.6
25 common bile duct neoplasm 12.4
26 bile duct carcinoma in situ 12.4
27 squamous cell bile duct carcinoma 12.3
28 distal biliary tract carcinoma 11.7
29 biliary tract cancer 11.5
30 klatskin's tumor 11.5
31 extrahepatic bile duct small cell adenocarcinoma 11.5
32 extrahepatic bile duct adenocarcinoma 11.5
33 liver benign neoplasm 11.3
34 biliary tract benign neoplasm 11.3
35 liver sarcoma 11.3
36 brain ependymoma 10.6 EGFR TP53
37 plasma cell leukemia 10.6 CCND1 NCAM1
38 benign breast adenomyoepithelioma 10.5 EGFR KRT7
39 estrogen-receptor positive breast cancer 10.5 CCND1 EGFR TP53
40 ovarian serous cystadenofibroma 10.5 MUC1 NCAM1
41 mature b-cell neoplasm 10.5 IL6 NCAM1 TP53
42 breast scirrhous carcinoma 10.5 EGFR MUC1
43 endometrial stromal sarcoma 10.5 CCND1 IL6 TP53
44 gliosarcoma 10.5 EGFR MMP2 TP53
45 male reproductive organ cancer 10.5 CCND1 TP53 VEGFA
46 oral cavity cancer 10.5 EGFR TP53 VEGFA
47 primary peritoneal carcinoma 10.5 EGFR TP53 VEGFA
48 rare adenocarcinoma of the breast 10.5 KRAS TP53
49 connective tissue cancer 10.4 MSLN TP53 VEGFA
50 cholangitis 10.4

Graphical network of the top 20 diseases related to Bile Duct Cancer:



Diseases related to Bile Duct Cancer

Symptoms & Phenotypes for Bile Duct Cancer

GenomeRNAi Phenotypes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.16 EGFR HRAS KRAS MUC1 NCAM1
2 Decreased viability GR00106-A-0 10.16 KRAS
3 Decreased viability GR00221-A-1 10.16 EGFR HRAS KRAS
4 Decreased viability GR00221-A-2 10.16 HRAS KRAS
5 Decreased viability GR00221-A-3 10.16 HRAS
6 Decreased viability GR00221-A-4 10.16 EGFR
7 Decreased viability GR00301-A 10.16 KRAS
8 Decreased viability GR00381-A-1 10.16 KRAS
9 Decreased viability GR00402-S-2 10.16 EGFR HRAS KRAS MUC1 NCAM1
10 Decreased cell migration GR00055-A-1 9.73 EGFR HRAS KRAS MET MUC1 NCAM1
11 Decreased viability in esophageal squamous lineage GR00235-A 9.65 AFP CCND1 CDKN2A HRAS IL6 KRAS
12 Reduced mammosphere formation GR00396-S 9.32 AFP CCND1 EGFR HRAS KRAS KRT7

MGI Mouse Phenotypes related to Bile Duct Cancer:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 AFP ASPH CCND1 CDKN2A EGFR HRAS
2 behavior/neurological MP:0005386 10.39 AFP CCND1 CDKN2A HRAS IL6 KRAS
3 cardiovascular system MP:0005385 10.38 ASPH CCND1 CDKN2A EGFR HRAS IL6
4 digestive/alimentary MP:0005381 10.36 ASPH CCND1 CDKN2A EGFR HRAS IL6
5 growth/size/body region MP:0005378 10.35 ASPH CCND1 CDKN2A EGFR HRAS IL6
6 cellular MP:0005384 10.34 CCND1 CDKN2A EGFR IL6 KRAS KRT7
7 mortality/aging MP:0010768 10.34 AFP ASPH CCND1 CDKN2A EGFR HRAS
8 endocrine/exocrine gland MP:0005379 10.32 AFP CCND1 CDKN2A EGFR HRAS IL6
9 craniofacial MP:0005382 10.29 ASPH CCND1 EGFR HRAS KRAS MET
10 immune system MP:0005387 10.29 CCND1 CDKN2A EGFR IL6 KRAS MET
11 neoplasm MP:0002006 10.27 AFP ASPH CCND1 CDKN2A EGFR HRAS
12 nervous system MP:0003631 10.21 CCND1 CDKN2A EGFR HRAS IL6 KRAS
13 integument MP:0010771 10.19 CCND1 CDKN2A EGFR HRAS IL6 KRAS
14 muscle MP:0005369 10.18 ASPH CDKN2A EGFR IL6 KRAS MET
15 liver/biliary system MP:0005370 10.16 AFP CDKN2A EGFR IL6 KRAS MET
16 limbs/digits/tail MP:0005371 10.07 ASPH EGFR KRAS MET SMAD4 TP53
17 normal MP:0002873 10.07 CCND1 EGFR HRAS KRAS MET MMP2
18 renal/urinary system MP:0005367 9.97 EGFR HRAS IL6 KRAS KRT7 MET
19 reproductive system MP:0005389 9.96 AFP ASPH CCND1 CDKN2A EGFR IL6
20 no phenotypic analysis MP:0003012 9.95 CDKN2A EGFR HRAS KRAS MET TP53
21 respiratory system MP:0005388 9.85 CCND1 CDKN2A EGFR HRAS IL6 KRAS
22 skeleton MP:0005390 9.65 CCND1 CDKN2A EGFR HRAS IL6 KRAS
23 vision/eye MP:0005391 9.36 CCND1 CDKN2A EGFR IL6 KRAS MET

Drugs & Therapeutics for Bile Duct Cancer

Drugs for Bile Duct Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 338)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
2
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
3
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Etomidate Approved Phase 4 33125-97-2 667484 36339
8
Meperidine Approved Phase 4 57-42-1 4058
9
Bilirubin Phase 4,Not Applicable 635-65-4, 69853-43-6 21252250 5280352
10 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
13 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Cyclooxygenase 2 Inhibitors Phase 4
16 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
18 Cyclooxygenase Inhibitors Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
20 arginine Phase 4
21 Omega 3 Fatty Acid Phase 4
22 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
24 Platelet Aggregation Inhibitors Phase 4
25 Anesthetics, General Phase 4,Phase 3,Not Applicable
26 Anesthetics, Inhalation Phase 4,Not Applicable
27 Anesthetics Phase 4,Phase 3,Not Applicable
28 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29
Bismuth Phase 4,Phase 3 7440-69-9 105143 16682734
30 GABA Modulators Phase 4,Not Applicable
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hypnotics and Sedatives Phase 4,Not Applicable
33 GABA Agents Phase 4,Not Applicable
34 Ulipristal acetate Phase 4 126784-99-4
35 Anti-Anxiety Agents Phase 4,Phase 3
36 Narcotics Phase 4,Phase 3,Not Applicable
37 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
38 Adjuvants, Anesthesia Phase 4,Phase 3
39 Psychotropic Drugs Phase 4,Phase 3
40 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
41 Tranquilizing Agents Phase 4,Phase 3
42
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
44
Trioxsalen Approved Phase 2, Phase 3,Phase 3,Not Applicable 3902-71-4 5585
45
Fluorouracil Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 51-21-8 3385
46
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
47
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 68538-85-2
48
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
49
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 526)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
2 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
3 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
4 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
5 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
8 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
10 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
11 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
12 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
13 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
14 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
15 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
16 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
17 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
18 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Unknown status NCT01755013 Phase 2, Phase 3
19 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Unknown status NCT00653978 Phase 3
20 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
21 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
22 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
23 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
24 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
25 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
26 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
27 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
28 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
29 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
30 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
31 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
32 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
33 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
34 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
35 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
36 Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
37 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
38 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
39 HAIC Versus Systemic Chemotherapy for Unresectable ICC Recruiting NCT03771846 Phase 3 gemcitabine, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
40 Treatment of Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
41 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
42 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
43 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
44 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
45 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
46 Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L Recruiting NCT02232490 Phase 3
47 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
48 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
49 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
50 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin

Search NIH Clinical Center for Bile Duct Cancer

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Cancer

Anatomical Context for Bile Duct Cancer

MalaCards organs/tissues related to Bile Duct Cancer:

42
Liver, Breast, Lung, Testes, Skin, Pancreas, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Bile Duct Cancer:

20
The Bile Duct

Publications for Bile Duct Cancer

Articles related to Bile Duct Cancer:

(show top 50) (show all 688)
# Title Authors Year
1
Massive hemobilia following plastic stent removal in common bile duct cancer associated with primary sclerosing cholangitis (with video). ( 30056613 )
2019
2
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer. ( 30729623 )
2019
3
The Comparison of Inflammation-Based Prognostic Scores in Patients With Extrahepatic Bile Duct Cancer After Pancreaticoduodenectomy. ( 30769246 )
2019
4
Prognostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection versus R0 after additional resection. ( 30849218 )
2019
5
microRNA-329 suppresses epithelial-to-mesenchymal transition and lymph node metastasis in bile duct cancer by inhibiting laminin subunit beta 3. ( 30887508 )
2019
6
Risk factors associated with locoregional failure and estimation of survival after curative resection for patients with distal bile duct cancer. ( 30911043 )
2019
7
A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin. ( 30941639 )
2019
8
Validation of the Eighth American Joint Committee on Cancer Staging System for Distal Bile Duct Carcinoma. ( 29510611 )
2019
9
Upregulated lncRNA-UCA1 contributes to metastasis of bile duct carcinoma through regulation of miR-122/CLIC1 and activation of the ERK/MAPK signaling pathway. ( 31106658 )
2019
10
Transparenchymal glissonean approach: a novel surgical technique for advanced perihilar bile duct cancer. ( 29063245 )
2018
11
Prognostic predictability of the new American Joint Committee on Cancer 8th staging system for distal bile duct cancer: limited usefulness compared with the 7th staging system. ( 29239127 )
2018
12
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. ( 29405274 )
2018
13
High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients. ( 29422250 )
2018
14
Bile duct angulation and tumor vascularity are useful radiographic features for differentiating pancreatic head cancer and intrapancreatic bile duct cancer. ( 29460125 )
2018
15
Ultra-early occlusion of the normal bile duct after uncovered self-expandable metallic stent placement in unresectable perihilar bile duct cancer. ( 29499092 )
2018
16
Bile duct segmental resection versus pancreatoduodenectomy for middle and distal common bile duct cancer. ( 29732355 )
2018
17
Patterns of failure after resection of extrahepatic bile duct cancer: implications for adjuvant radiotherapy indication and treatment volumes. ( 29739420 )
2018
18
Smoking, alcohol consumption, and risks for biliary tract cancer and intrahepatic bile duct cancer. ( 29760302 )
2018
19
MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer. ( 29860474 )
2018
20
Dual-organ invasion is associated with a lower survival rate than single-organ invasion distal bile duct cancer: A multicenter study. ( 30018404 )
2018
21
Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation. ( 30067440 )
2018
22
Author Correction: Dual-organ invasion is associated with a lower survival rate than single-organ invasion in distal bile duct cancer: A multicenter study. ( 30097619 )
2018
23
Pattern of distant metastases in primary extrahepatic bile-duct cancer: A SEER-based study. ( 30277653 )
2018
24
Inverse Prognostic Relationships of 18F-FDG PET/CT Metabolic Parameters in Patients with Distal Bile Duct Cancer Undergoing Curative Surgery. ( 30344781 )
2018
25
Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer. ( 30405779 )
2018
26
Discovering proteins for chemoprevention and chemotherapy by curcumin in liver fluke infection-induced bile duct cancer. ( 30440021 )
2018
27
Trends in Incidence of Two Major Subtypes of Liver and Bile Duct Cancer: Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Southern Thailand, 1989-2030. ( 30675163 )
2018
28
Impact of the histological phenotype of extrahepatic bile duct carcinoma. ( 29387397 )
2018
29
miR-122-5p Inhibits the Proliferation, Invasion and Growth of Bile Duct Carcinoma Cells by Targeting ALDOA. ( 30121648 )
2018
30
CD8+ T Cells That Coexpress RORγt and T-bet Are Functionally Impaired and Expand in Patients with Distal Bile Duct Cancer. ( 28053236 )
2017
31
Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer. ( 28064229 )
2017
32
Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. ( 28084572 )
2017
33
Role of adjuvant radiotherapy for localized extrahepatic bile duct cancer. ( 28118028 )
2017
34
Karnofsky Performance Score Is Predictive of Survival After Palliative Irradiation of Metastatic Bile Duct Cancer. ( 28179357 )
2017
35
Preoperative Cholangitis Affects Survival Outcome in Patients with Extrahepatic Bile Duct Cancer. ( 28290140 )
2017
36
Ceruloplasmin as a prognostic marker in patients with bile duct cancer. ( 28423673 )
2017
37
Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer. ( 28447209 )
2017
38
Brachytherapy in the treatment of bile duct cancer - a tough challenge. ( 28533809 )
2017
39
Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer. ( 28624624 )
2017
40
Synchronous Gall Bladder and Bile Duct Cancer: A Short Series of Seven Cases and a Brief Review of Literature. ( 28663675 )
2017
41
Portal vein stenting for portal vein stenosis caused by bile duct cancer. ( 28676419 )
2017
42
Hepatobiliary and Pancreatic: Portal vein stent for local recurrence of bile duct cancer. ( 28752686 )
2017
43
Validation of Feasibility of Magnetic Resonance Imaging for the Measurement of Depth of Tumor Invasion in Distal Bile Duct Cancer According to the New American Joint Committee on Cancer Staging System. ( 28780173 )
2017
44
Prognostic Impact of Extracapsular Lymph Node Invasion and Myofibroblastic Activity in Extrahepatic Bile Duct Cancer. ( 28912637 )
2017
45
Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery. ( 28937265 )
2017
46
Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution. ( 29100449 )
2017
47
Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer. ( 29187494 )
2017
48
Phosphorylated Akt Expression as a Favorable Prognostic Factor for Patients Undergoing Curative Resection and Adjuvant Chemoradiotherapy for Proximal Extrahepatic Bile Duct Cancer. ( 25171299 )
2017
49
Reproductive factors and gallbladder/bile duct cancer: a population-based cohort study in Japan. ( 27164185 )
2017
50
Relationship between the surgical margin status, prognosis, and recurrence in extrahepatic bile duct cancer patients. ( 27491729 )
2017

Variations for Bile Duct Cancer

Cosmic variations for Bile Duct Cancer:

9 (show top 50) (show all 3045)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6971229 ZRSR2 small intestine,NS,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 0
2 COSM4767818 ZNF521 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1495T>C p.S499P 18:25226423-25226423 0
3 COSM4767811 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.10571A>C p.K3524T 8:76864285-76864285 0
4 COSM4767807 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1738G>T p.G580* 8:76705826-76705826 0
5 COSM4767809 ZFHX4 biliary tract,gallbladder,carcinoma,adenocarcinoma c.4616G>A p.R1539H 8:76851537-76851537 0
6 COSM6974042 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.6964C>T p.R2322* 16:72795718-72795718 0
7 COSM6973250 ZFHX3 small intestine,NS,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 0
8 COSM6845179 ZFHX3 small intestine,NS,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 0
9 COSM6957143 ZFHX3 biliary tract,bile duct,carcinoma,adenocarcinoma c.3529+1G>A p.? 16:72829778-72829778 0
10 COSM4767679 ZFHX3 biliary tract,gallbladder,carcinoma,adenocarcinoma c.3003G>A p.L1001L 16:72950682-72950682 0
11 COSM6928728 YAP1 biliary tract,bile duct,carcinoma,adenocarcinoma c.434C>G p.T145S 11:102114256-102114256 0
12 COSM6986174 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.273G>T p.W91C 2:61522639-61522639 0
13 COSM6985358 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.338C>T p.T113M 2:61502274-61502274 0
14 COSM6975271 XPO1 biliary tract,bile duct,carcinoma,adenocarcinoma c.729G>T p.E243D 2:61498703-61498703 0
15 COSM6913839 WT1 small intestine,NS,carcinoma,adenocarcinoma c.538G>T p.D180Y 11:32428524-32428524 0
16 COSM4767666 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.237C>T p.G79G 11:32434905-32434905 0
17 COSM6971786 WT1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1025T>C p.M342T 11:32396277-32396277 0
18 COSM1130534 U2AF1 small intestine,NS,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 0
19 COSM166866 U2AF1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.101C>T p.S34F 21:43104346-43104346 0
20 COSM4767802 TSHR biliary tract,gallbladder,carcinoma,adenocarcinoma c.1446C>A p.Y482* 14:81143504-81143504 0
21 COSM6917759 TSC2 small intestine,NS,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 0
22 COSM968394 TSC2 biliary tract,bile duct,carcinoma,adenocarcinoma c.1819G>A p.A607T 16:2070558-2070558 0
23 COSM6968949 TSC2 small intestine,NS,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 0
24 COSM168829 TSC2 biliary tract,gallbladder,carcinoma,adenocarcinoma c.170G>A p.R57H 16:2050431-2050431 0
25 COSM6939562 TSC2 biliary tract,bile duct,carcinoma,adenocarcinoma c.1783C>T p.Q595* 16:2070522-2070522 0
26 COSM4767800 TSC2 biliary tract,gallbladder,carcinoma,adenocarcinoma c.230C>T p.A77V 16:2053346-2053346 0
27 COSM6923580 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.2551C>T p.Q851* 9:132900789-132900789 0
28 COSM1238034 TSC1 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1041G>A p.W347* 9:132911102-132911102 0
29 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.737+1G>A p.? 9:132921362-132921362 0
30 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,adenocarcinoma c.1475G>T p.R492L 19:58549053-58549053 0
31 COSM6964832 TRAF7 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1884G>T p.W628C 16:2176270-2176270 0
32 COSM44388 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.853G>T p.E285* 17:7673767-7673767 0
33 COSM44463 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.848G>T p.R283L 17:7673772-7673772 0
34 COSM10660 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.818G>A p.R273H 17:7673802-7673802 0
35 COSM10812 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.722C>T p.S241F 17:7674241-7674241 0
36 COSM44745 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.410T>A p.L137Q 17:7675202-7675202 0
37 COSM10659 TP53 small intestine,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 17:7673803-7673803 0
38 COSM10662 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 0
39 COSM10687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.527G>A p.C176Y 17:7675085-7675085 0
40 COSM10731 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.707A>G p.Y236C 17:7674256-7674256 0
41 COSM10722 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.853G>A p.E285K 17:7673767-7673767 0
42 COSM10935 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.722C>A p.S241Y 17:7674241-7674241 0
43 COSM11196 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.734G>T p.G245V 17:7674229-7674229 0
44 COSM11286 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.1015G>T p.E339* 17:7670694-7670694 0
45 COSM43778 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.713G>T p.C238F 17:7674250-7674250 0
46 COSM44309 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.440T>G p.V147G 17:7675172-7675172 0
47 COSM44426 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.568C>G p.P190A 17:7674963-7674963 0
48 COSM10648 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 0
49 COSM10758 TP53 biliary tract,gallbladder,carcinoma,adenocarcinoma c.659A>G p.Y220C 17:7674872-7674872 0
50 COSM11073 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 0

Expression for Bile Duct Cancer

Search GEO for disease gene expression data for Bile Duct Cancer.

Pathways for Bile Duct Cancer

Pathways related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CCND1 EGFR HRAS IL6 KRAS MET
2
Show member pathways
13.93 CCND1 CDKN2A EGFR HRAS IL6 KRAS
3
Show member pathways
13.8 CCND1 CDKN2A EGFR HRAS IL6 KRAS
4
Show member pathways
13.6 EGFR HRAS IL6 KRAS MET SMAD4
5
Show member pathways
13.58 CD24 EGFR HRAS KRAS KRT7 MET
6
Show member pathways
13.4 CCND1 EGFR HRAS IL6 KRAS MET
7
Show member pathways
13.12 EGFR HRAS IL6 KRAS MET TP53
8
Show member pathways
13.07 CCND1 EGFR HRAS IL6 KRAS MET
9
Show member pathways
13.06 CCND1 CDKN2A EGFR HRAS IL6 KRAS
10
Show member pathways
13.01 EGFR HRAS IL6 KRAS TP53 VEGFA
11
Show member pathways
12.98 CCND1 EGFR HRAS KRAS MET VEGFA
12
Show member pathways
12.97 CCND1 CDKN2A EGFR HRAS KRAS SMAD4
13 12.85 EGFR HRAS KRAS MET TP53 VEGFA
14
Show member pathways
12.84 CCND1 CDKN2A EGFR HRAS KRAS MET
15
Show member pathways
12.79 EGFR HRAS KRAS MET VEGFA
16
Show member pathways
12.79 EGFR HRAS KRAS MET TP53
17
Show member pathways
12.76 CCND1 EGFR HRAS KRAS MMP2 VEGFA
18
Show member pathways
12.69 EGFR HRAS IL6 KRAS MMP2 TP53
19
Show member pathways
12.68 CCND1 EGFR HRAS KRAS MET TP53
20
Show member pathways
12.58 EGFR HRAS KRAS MET TP53
21
Show member pathways
12.56 CCND1 EGFR HRAS KRAS MMP2 MUC1
22
Show member pathways
12.55 CCND1 CDKN2A EGFR HRAS IL6 KRAS
23
Show member pathways
12.53 EGFR HRAS KRAS MET TP53
24 12.53 CCND1 CDKN2A EGFR HRAS KRAS MET
25
Show member pathways
12.49 CCND1 EGFR HRAS IL6 KRAS
26
Show member pathways
12.48 HRAS KRAS MUC1 MUC5AC
27
Show member pathways
12.47 CCND1 EGFR HRAS KRAS
28
Show member pathways
12.45 EGFR HRAS MET VEGFA
29
Show member pathways
12.45 CCND1 HRAS MET TP53
30
Show member pathways
12.45 EGFR HRAS IL6 KRAS MET
31 12.44 CCND1 CDKN2A HRAS IL6 KRAS SMAD4
32 12.42 CCND1 CDKN2A SMAD4 TP53
33 12.42 CCND1 CDKN2A EGFR HRAS IL6 KRAS
34 12.39 CCND1 CDKN2A HRAS KRAS TP53
35
Show member pathways
12.34 EGFR IL6 KRAS MET TP53
36
Show member pathways
12.31 HRAS KRAS TP53 VEGFA
37
Show member pathways
12.31 CCND1 EGFR HRAS KRAS MET TP53
38
Show member pathways
12.3 EGFR HRAS KRAS VEGFA
39
Show member pathways
12.29 EGFR HRAS IL6 MUC5AC
40 12.29 CCND1 CDKN2A HRAS IL6 KRAS TP53
41 12.27 CCND1 EGFR HRAS KRAS MET MMP2
42 12.26 CCND1 EGFR KRAS SMAD4 TP53 VEGFA
43 12.25 CCND1 EGFR HRAS KRAS MET TP53
44
Show member pathways
12.23 CCND1 EGFR HRAS IL6 MMP2
45
Show member pathways
12.18 EGFR HRAS IL6 KRAS MET SMAD4
46 12.18 AFP IL6 MET NCAM1 VEGFA
47
Show member pathways
12.18 CCND1 EGFR HRAS IL6 KRAS SMAD4
48 12.17 CCND1 HRAS KRAS SMAD4
49 12.17 AFP EGFR MET MMP2 TP53
50 12.16 CDKN2A MMP2 SMAD4 TP53 VEGFA

GO Terms for Bile Duct Cancer

Cellular components related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 AFP EGFR IL6 MMP2 MSLN MUC1
2 extracellular region GO:0005576 9.7 AFP CEACAM5 EGFR IL6 MET MMP2
3 anchored component of membrane GO:0031225 9.46 CD24 CEACAM5 MSLN NCAM1
4 cell surface GO:0009986 9.17 CD24 CEACAM5 EGFR MET MSLN NCAM1
5 cytoplasm GO:0005737 10.1 AFP ASPH CCND1 CDKN2A EGFR HRAS

Biological processes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.96 EGFR HRAS MET SMAD4 TP53
2 negative regulation of apoptotic process GO:0043066 9.95 CEACAM5 EGFR IL6 TP53 VEGFA
3 negative regulation of cell proliferation GO:0008285 9.93 ASPH CDKN2A HRAS IL6 SMAD4 TP53
4 cellular protein metabolic process GO:0044267 9.91 AFP IL6 MMP2 MSLN
5 positive regulation of gene expression GO:0010628 9.88 CDKN2A HRAS IL6 KRAS TP53 VEGFA
6 response to hypoxia GO:0001666 9.87 CD24 MMP2 SMAD4 VEGFA
7 MAPK cascade GO:0000165 9.83 EGFR HRAS KRAS MET NCAM1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 EGFR IL6 VEGFA
9 regulation of protein stability GO:0031647 9.79 ASPH CDKN2A KRAS
10 response to glucocorticoid GO:0051384 9.77 CCND1 IL6 KRAS
11 positive regulation of epithelial cell proliferation GO:0050679 9.76 EGFR HRAS VEGFA
12 positive regulation of protein phosphorylation GO:0001934 9.72 CCND1 EGFR HRAS KRAS VEGFA
13 intrinsic apoptotic signaling pathway GO:0097193 9.67 CD24 HRAS TP53
14 liver development GO:0001889 9.67 CCND1 EGFR KRAS MET
15 commissural neuron axon guidance GO:0071679 9.63 NCAM1 VEGFA
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 EGFR TP53
17 mitotic G1 DNA damage checkpoint GO:0031571 9.59 CCND1 TP53
18 response to isolation stress GO:0035900 9.58 HRAS KRAS
19 Ras protein signal transduction GO:0007265 9.56 CDKN2A HRAS KRAS TP53
20 positive regulation of MAPK cascade GO:0043410 9.54 HRAS IL6
21 response to UV-A GO:0070141 9.51 CCND1 EGFR
22 cytokine-mediated signaling pathway GO:0019221 9.5 CCND1 IL6 KRAS MMP2 MUC1 TP53
23 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.46 HRAS KRAS MUC1 MUC5AC
24 positive regulation of MAP kinase activity GO:0043406 9.02 CD24 EGFR HRAS KRAS VEGFA
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 CDKN2A EGFR HRAS IL6 MET SMAD4
26 positive regulation of cell proliferation GO:0008284 10 CCND1 EGFR HRAS IL6 KRAS VEGFA

Molecular functions related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 AFP ASPH CCND1 CD24 CDKN2A EGFR
2 protein kinase binding GO:0019901 9.35 CCND1 CD24 CDKN2A EGFR TP53
3 protein phosphatase binding GO:0019903 9.33 EGFR MET TP53

Sources for Bile Duct Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....